In summary, this study aimed to provide insights into the role of XAB2 in CRC, revealing the potential of targeting the USP10/XAB2/ANXA2 axis to enhance chemotherapy sensitivity in CRC. The gene discussed is ANXA2; the disease is colorectal carcinoma.